2-(2-溴苯基)-吡咯烷 | 129540-24-5

• 物质功能分类: 化学试剂 - 有机试剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-(2-溴苯基)-吡咯烷
• 英文名称: 2-(2-bromophenyl)pyrrolidine
• CAS: 129540-24-5
• 化学式: C₁₀H₁₂BrN
• mdl: MFCD02663433
• 分子量: 226.116
• InChiKey: BSLGMIVYENBFFY-UHFFFAOYSA-N

物化性质

• 沸点：
  274℃
• 密度：
  1.369
• 闪点：
  120℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-(2-溴苯基)-吡咯烷 在 sodium hydroxide 、 PPA 、 硼烷四氢呋喃络合物 作用下， 反应 0.5h， 生成 cis-10-bromo-1,2,3,5,6,10b-hexahydro-6-<4-(methylthio)phenyl>pyrrolo<2,1-a>isoquinoline
  参考文献：
  名称：

  Pyrroloisoquinoline antidepressants. 3. A focus on serotonin

  摘要：

  A collection of hexahydropyrroloisoquinoline derivatives (1-22), which represent a class of compounds that inhibit the neuronal uptake of dopamine (DA), norepinephrine (NE), and serotonin (5-HT), was investigated in vivo for serotonin-potentiating properties in the mouse head-twitch and rat serotonin syndrome assays. The p-methylthio compound 3b (McN-5652-Z) was found to possess exceptional activity in these assays, and the activity was attributable almost exclusively to the (+)-6S,10bR enantiomer. Ten closely related analogues were synthesized, tested, and compared among themselves and with some previously prepared compounds, both in vivo and in vitro. Several trans diastereomers exhibited strong inhibition of 5-HT uptake and substantial potentiation of 5-HT, while the cis diastereomers (3a, 4a, and 10a) tested were virtually devoid of such activity. Although 3b was only moderately selective in inhibiting the uptake of 5-HT vs NE, its 10-substituted analogues 4b, 7b-9b had improved 5-HT selectivity relative to NE, to the extent of 20-25 times (150-200 times relative to DA). Of these more selective compounds (in vitro), only 4b and 7b had substantial activity in vivo. Sulfoxide 11b appeared to function as a prodrug of 3b in vivo.

  DOI：

  10.1021/jm00172a018
• 作为产物：
  描述：

  2-(2-bromophenyl)-1-pyrroline 在 sodium tetrahydroborate 、 溶剂黄146 、 盐酸 、 水 、 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 生成 2-(2-溴苯基)-吡咯烷
  参考文献：
  名称：

  (PYRROLIDIN-2-YL)PHENYL DERIVATIVES

  摘要：

  该发明涉及具有通式I的（吡咯啉-2-基）苯基衍生物，其中R1为（C1-4）烷基、卤代（C1-4）烷基、（C1-4）烷氧基或卤代（C1-4）烷氧基；R2为H、（C1-4）烷基、卤代（C1-4）烷基、（C1-4）烷氧基、卤代（C1-4）烷氧基或卤素；R3为H、（C1-4）烷基或卤代（C1-4）烷基；R4为H、（C1-4）烷基或卤代（C1-4）烷基；R5为H、（C1-4）烷基或卤代（C1-4）烷基；或者当R4和R5与同一碳原子结合时，它们可以与碳原子一起形成一个可选择地取代卤素的螺环（C3-6）环烷基基团；R6为H、（C1-4）烷基、卤代（C1-4）烷基、（C1-4）烷氧基、卤代（C1-4）烷氧基或卤素；或其药学上可接受的盐，以及含有这些（吡咯啉-2-基）苯基衍生物的药物组合物，以及这些（吡咯啉-2-基）苯基衍生物用于治疗疼痛，如神经痛或炎症性疼痛。

  公开号：

  US20100113493A1

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS COMME INHIBITEURS DE TRK
  申请人：IRM LLC

  公开号：WO2012034095A1

  公开（公告）日：2012-03-15

  The invention provides compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity. wherein: and the rest of the variables are as specified in the claims.

  本发明提供了公式(I)的化合物，包含此类化合物的药物组合物以及使用此类化合物治疗或预防与异常或失调的TRK激酶活性相关疾病或失调的方法。其中：其余变量如权利要求中所述。
• 一类组蛋白乙酰化酶p300抑制剂及其用途
  申请人：海创药业股份有限公司

  公开号：CN111217802B

  公开（公告）日：2021-10-08

  本发明公开了一类组蛋白乙酰化酶p300抑制剂及其用途，属于药物化学技术领域。本发明公开了一类式(Ⅰ)所示化合物、或其立体化学异构体，或其溶剂合物、或其药学上可接受的盐。本发明公开的化合物能够有效抑制组蛋白乙酰化酶p300的活性，能够有效抑制多种肿瘤细胞的增殖活性。同时，本发明化合物与CDK4/6抑制剂联用，在抑制肿瘤细胞的增殖中发挥了协同作用。因此，本发明的化合物在制备组蛋白乙酰化酶抑制剂，制备预防和/或治疗癌症、代谢类疾病、神经类疾病或炎症的药物以及联合用药物中具有非常好的应用前景。
• [EN] COMPOUNDS FOR THE MODULATION OF CYCLOPHILINS FUNCTION<br/>[FR] COMPOSÉS POUR LA MODULATION DE LA FONCTION DES CYCLOPHILINES
  申请人：UNIV COURT UNIV OF EDINBURGH

  公开号：WO2020043831A1

  公开（公告）日：2020-03-05

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof useful as inhibitors of Cyclophilins and modulators of cyclophilin-like proteins. The invention also relates to uses of said compounds in the treatment of various disorders. Formula (I), wherein: R1 and R2 are each independently is selected from the group consisting of -R, -haloalkyl, -hydroxyalkyl, -OR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, and - N(R)2; wherein R2 could also be a sulphide; each R is independently hydrogen, C 1-6 aliphatic, C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, sulphur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms selected from nitrogen, oxygen, or sulphur; R3 is Formual (Ia) selected from the group consisting of -OEt, and wherein R5 and R6 are independently selected from the group consisting of H, halide, methoxy, thiomethyl, morpholine and trifluoromethyl;R4 is selected from the group consisting of C1-6-alkyl-, and R4.1-CH2- wherein, R4.1 is C3-6-cycloalkyl-, a 5-6 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, sulphur; optionally substituted with one R4.1.1 wherein, R4.1.1 is selected from -H, C1-4-alkyl, optionally substituted with one substituent selected from H2N(O)C- or EtO(O)C-;X is carbon or nitrogen; A is selected from the group consisting of 6 membered unsaturated ring, with 1-3 nitrogen atoms, which is optionally substituted by -NH2,and Formula (Ib), wherein ring B is a fused 5-10 membered saturated or partially unsaturated heterocyclic mono- bicyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen or sulphur, which is optionally substituted by -OH; and m is 1 or 2; and n is 1 or 2.

  本发明涉及式(I)的化合物或其药学上可接受的盐，其作为环肽酶的抑制剂和环肽酶样蛋白的调节剂。该发明还涉及所述化合物在治疗各种疾病中的用途。式(I)中：R1和R2各自独立地选自由-R、-卤代烷基、-羟基烷基、-OR、-C(O)R、-CO2R、-C(O)N(R)2、-NRC(O)R和-N(R)2等组成的群；其中R2也可以是硫化物；每个R独立地是氢、C1-6脂肪基、C3-10芳基、一个3-8成员饱和或部分不饱和的碳环、一个具有1-4个异原子（从氮、氧、硫中独立选择）的3-7成员杂环、或一个具有1-4个异原子（从氮、氧、硫中选择）的5-6成员单环杂芳基；R3是式(Ia)中选自-OEt的群，其中R5和R6各自独立地选自H、卤素、甲氧基、硫甲基、吗啉和三氟甲基的群；R4选自C1-6-烷基-和R4.1-CH2-，其中，R4.1是C3-6环烷基-、一个具有1-4个异原子（从氮、氧、硫中独立选择）的5-6成员杂环，可选地用一个R4.1.1取代，其中R4.1.1选自-H、C1-4-烷基，可选地用一个取代基（从H2N(O)C-或EtO(O)C-中选择）取代；X是碳或氮；A选自具有1-3个氮原子的6成员不饱和环，可选地用-NH2取代；和式(Ib)，其中环B是一个融合的5-10成员饱和或部分不饱和的杂环单双环，具有1-3个从氮、氧或硫中选择的异原子，可选地用-OH取代；m为1或2；n为1或2。
• [EN] 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES<br/>[FR] DÉRIVÉS DE 1H-PYRROLO[2,3-B]PYRIDINE COMME INHIBITEURS BCL-2 POUR LE TRAITEMENT DES MALADIES NÉOPLASIQUES ET AUTO-IMMUNES
  申请人：GUANGZHOU LUPENG PHARMACEUTICAL COMPANY LTD

  公开号：WO2021133817A1

  公开（公告）日：2021-07-01

  The present invention relates to lH-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for treating neoplastic, autoimmune or neurodegenerative diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 162 to 233; examples 1 to 8; table; compound examples cpd-1 to cpd-135; biological examples 1 to 4).

  本发明涉及LH-吡咯并[2,3-b]吡啶衍生物及相关化合物作为BCL-2抑制剂，用于治疗肿瘤、自身免疫或神经退行性疾病。本说明书披露了示例化合物的合成和表征，以及其药理学数据（例如第162至233页；示例1至8；表格；化合物示例cpd-1至cpd-135；生物学示例1至4）。
• [EN] ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN<br/>[FR] DÉRIVÉS (PYRROLIDIN-2-YL)PHÉNYLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE LA DOULEUR
  申请人：ORGANON NV

  公开号：WO2010052198A1

  公开（公告）日：2010-05-14

  The invention relates to (pyrrolidin-2-yl)phenyl derivatives having the general Formula (I), wherein R1 is (C1-4)alkyl, halo(C1-4)alkyl, (C1-4)alkyloxy, or halo(C1-4)alkyloxy; R2 is H, (C1-4)alkyl, halo(C1-4)alkyl, (C1-4)alkyloxy, halo(C1-4)alkyloxy or halogen; R3 is H, (C1-4)alkyl or halo(C1-4)alkyl; R4 is H, (C1-4)alkyl or halo(C1-4)alkyl; R5 is H, (C1-4)alkyl or halo(C1-4)alkyl; or R4 and R5, when bonded to the same carbon atom, can together with the carbon atom form a spiro(C3-6)cycloalkyl group, optionally substituted with halogen; R6 is H, (C1-4)alkyl, halo(C1-4)alkyl, (C1-4)alkyloxy, halo(C1-4)alkyloxy or halogen; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these (pyrrolidin-2-yl)phenyl derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.

  该发明涉及具有通式（I）的（吡咯烷-2-基）苯基衍生物，其中R1为（C1-4）烷基，卤代（C1-4）烷基，（C1-4）烷氧基或卤代（C1-4）烷氧基；R2为H，（C1-4）烷基，卤代（C1-4）烷基，（C1-4）烷氧基，卤代（C1-4）烷氧基或卤素；R3为H，（C1-4）烷基或卤代（C1-4）烷基；R4为H，（C1-4）烷基或卤代（C1-4）烷基；R5为H，（C1-4）烷基或卤代（C1-4）烷基；或者R4和R5，当与同一碳原子结合时，可以与碳原子一起形成一个可选地被卤素取代的螺环（C3-6）环烷基基团；R6为H，（C1-4）烷基，卤代（C1-4）烷基，（C1-4）烷氧基，卤代（C1-4）烷氧基或卤素；或其药学上可接受的盐，以及包含它们的制药组合物，以及这些（吡咯烷-2-基）苯基衍生物用于治疗疼痛，如神经性疼痛或炎症性疼痛。